These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Life after DIAS II. Donnan GA; Davis SM Int J Stroke; 2007 Nov; 2(4):236-7. PubMed ID: 18705921 [No Abstract] [Full Text] [Related]
31. A parallel phase I/II clinical trial design for combination therapies. Huang X; Biswas S; Oki Y; Issa JP; Berry DA Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495 [TBL] [Abstract][Full Text] [Related]
32. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside. Sakamoto J; Morita S Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175 [TBL] [Abstract][Full Text] [Related]
33. Comparison of randomization techniques for clinical trials with data from the HOMERUS-trial. Verberk WJ; Kroon AA; Kessels AG; Nelemans PJ; Van Ree JW; Lenders JW; Thien T; Bakx JC; Van Montfrans GA; Smit AJ; Beltman FW; De Leeuw PW Blood Press; 2005; 14(5):306-14. PubMed ID: 16257877 [TBL] [Abstract][Full Text] [Related]
34. [Clinical trials. When and why: the principle of randomization and double-blind method]. de Giuli F Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):973-5. PubMed ID: 12497860 [No Abstract] [Full Text] [Related]
35. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
36. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
37. Pre-randomization and de-randomization in emergency medical research: new names and rigorous criteria for old methods. Hallstrom AP; Paradis NA Resuscitation; 2005 Apr; 65(1):65-9. PubMed ID: 15797277 [TBL] [Abstract][Full Text] [Related]
38. A three-outcome design for randomized comparative phase II clinical trials. Hong S; Wang Y Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879 [TBL] [Abstract][Full Text] [Related]
39. Examining heterogeneity in phase II trial designs may improve success in phase III. Tuma RS J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788 [No Abstract] [Full Text] [Related]